Compare MMI & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMI | RLAY |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2013 | 2020 |
| Metric | MMI | RLAY |
|---|---|---|
| Price | $29.58 | $7.84 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $29.00 | $16.00 |
| AVG Volume (30 Days) | 189.9K | ★ 2.2M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $751,284,000.00 | $8,355,000.00 |
| Revenue This Year | $11.94 | $20.47 |
| Revenue Next Year | $15.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.74 | N/A |
| 52 Week Low | $27.35 | $1.78 |
| 52 Week High | $42.53 | $8.36 |
| Indicator | MMI | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 51.09 | 62.89 |
| Support Level | $28.74 | $7.23 |
| Resistance Level | $30.30 | $8.36 |
| Average True Range (ATR) | 0.76 | 0.52 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 62.33 | 78.88 |
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).